STAT+: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data
The hope for many cancer patients who go through surgery is that they’ll be cured…
Category: ASCO24
STAT+: Oncologists turn to blood test for circulating tumor DNA, but questions remain on how to use the data
The hope for many cancer patients who go through surgery is that they’ll be cured…
Listen: Psychedelics at the FDA, ASCO recap, & MorphoSys update
How did advisers react to the first psychedelic therapy to go before the Food and…
STAT+: Novartis is flashing warning signs about the fate of its newly acquired myelofibrosis drug
CHICAGO — Something is off about the way Novartis is talking about pelabresib, its newly…
STAT+: ASCO Daily Recap: A CAR-T advance, money talk, and tossing the cancer treatment ‘sandwich’
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: At ASCO, AstraZeneca says its CAR-T therapy shrank solid liver tumors in early trial
CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with…
STAT+: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
Palliative care for cancer patients is found to be as effective given virtually as in person
CHICAGO — Comfort can be delivered to patients with advanced cancer virtually just as well…
STAT+: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
In patients with stage 3 lung cancer where a particular genetic mutation is present in…
STAT+: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a…
STAT+: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market
LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew…
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
STAT+: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers…
STAT+: With expectations rising, Corbus reveals new data on its ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor…
How can hospitals boost cancer screening rates? Researchers report that an AI helped
CHICAGO — People can be mightily reluctant to get a colonoscopy for reasons like cost,…
Listen: An ASCO preview & another Duchenne trial failure
Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do…
STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer
Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor…
STAT+: ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care
Thousands of cancer researchers and clinicians are flocking to Chicago for the American Society of…
STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some…
The HPV vaccine prevents cancer in men, too. Why do so few people get it?
You’d think if there were a vaccine that would prevent tens of thousands of cases…
STAT+: Setting the table: What to expect at this year’s ASCO meeting
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…